Tag: KERX

CHGS, DUSS & Extended Watchlist

China GengSheng Minerals, Inc. CHGS
–
After appearing on yesterday morning’s extended watchlist, CHGS came screaming out of the gate, running from .19 all the way up to .35 (+84%). The stock consolidated, and followed that initial run with two subsequent bounces, one from .24-.35 (+46%), and another from .28 to the day’s high at .39 (+39%).

A tip of the cap to anyone who was able to take advantage of some of the nearly 170% in cumulative intraday gains provided by CHGS, which can be seen on the following chart:

Dussault Apparel, Inc. DUSS
DUSS was the addition we made to the day’s watchlist in yesterday’s afternoon update. Following that alert, we saw a low of .0012, followed by a 25% run-up to the .0015 high-of-day where the stock closed.

As you can see on the annotated chart below, the next key area of resistance to watch for a break resides at .0024. A break past that point would put us in blue-sky breakout territory.

PLEASE NOTE: DUSS is a play that we selected from one of our daily scans. We were not compensated in any way to feature DUSS in our reports, however, owners of this newsletter did purchase two million (2,000,000) shares out of the open market.

Extended Watchlist:
KERX, GERN, ODP, BORN, FB, AAPL, XNY, RMTI

DRRX, PPHM & Extended Watchlist

Durect Corp. DRRX

We are putting DRRX on our radar this morning; it has recently come off of a bottom, and is gaining some momentum as it begins its recovery. Prior to May, this pharmaceutical play was trading at a base level well above 1.20, before seeing a large spike followed by a sharp dropoff. If DRRX can break through resistance at the 50DMA & 200DMA there’s a chance it could come up to fill that gap on the chart. A return to previous levels from here could yield gains of up to 20%

In addition to a connection with pharma giant Pfizer, the company has also gotten FDA acceptance of a New Drug Application (NDA) as outlined in yesterday’s PR:

CUPERTINO, Calif., June 20, 2013 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery. DURECT submitted the NDA as a 505(b)(2) application. The Prescription Drug User Fee Act (PDUFA) goal date (the date the FDA expects to complete its review of the NDA) has been confirmed as February 12, 2014.

Peregrine Pharmaceuticals, Inc. PPHM

Speaking of pharmaceutical plays, one of the stocks that we continuously monitor is PPHM. Many of you will remember back in May when the stock provided us with some serious opportunities for profit.

Recently PPHM has been in a marked downtrend, and as you can see on the chart below, indicators seem to confirm this fact. We are going to want to put this one on bottom watch over the next several sessions, as the resulting bounce/s could be significant.

Side Note: 

Since Ben Bernanke’s recent comments regarding the Fed’s upcoming tapering of quantitative easing measures, markets have been in freefall. If no reversal occurs and that remains the overall trend, we are going to want to keep an eye on SPY Puts, VIX/VXX Calls.

Extended Watchlist:
ONCI, ONCO, LIVE, KERX, MSTX  

HEMP, MJNA, CBIS, XCHC & Extended Watchlist

We’re continuing our medical marijuana coverage this morning, after the cannabis related stocks we mentioned on Friday each turned in a fine performance. We had a sizable influx of new subscribers over the weekend, so we’d like to take this opportunity to welcome all of our new friends and thank you for your support. You made a great choice when you signed up, and we will do our best to ensure that you are able to reap the rewards.
___

Each of the following stocks appeared on Friday’s report, and subsequently had a good session on Friday, but our coverage of these plays began way back in the fall, and in that time, have been very impressed with the results. Just look at the gains we’ve made from these cannabis stocks:

Medical Marijuana, Inc. MJNA

MJNA has traded in a range from .071 to .35 since we began following the stock, giving us the chance to rake in over 390% in profits.
___

Hemp, Inc. HEMP

HEMP took a mere four sessions following our original call to run from .027-.09 this fall, and more recently saw a low of .0222 (Jan. 7th) before hitting a high of .051 on Friday, for an opportunity at another 130%
___

Cannabis Science, Inc. CBIS

In the time since we first talked about CBIS, we’ve observed a range of .04-.099 (+148%).  Last week, CBIS was as low as .048 before hitting a high of .0749 on Friday for an added 56% in gains.
___

X-Change Corporation XCHC

XCHC is the newest among these to appear in our reports, and also had a killer week. It promptly gained 178% from .0521-.145 after we added it to our list of marijuana stocks last Monday.
___

Other stocks we’ve recently covered in this rapidly expanding field which have also made tremendous gains for us include: GRNH, ERBB, MWIP & PHOT. We’ve definitely gone over many of the most popular hemp plays on the OTC Markets, however, we’ve managed to root out a couple new ones to add to the mix. Allow us to also submit LATF and TRTC for your consideration. That brings our tracking list up to 10 stocks in one of the hottest, most cutting-edge market sectors of our time. For those of you who are indeed new to our mailing lists, you showed up during one of the most exciting periods in our more than ten years reporting on hot penny stocks.  
__

Extended Watchlist:
PPHM, KERX, RMTI, SONS, PEIX, BIOF, MOBI, ETRM